Exploring relief for Behçet’s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast

Giuseppe Lopalco; Maria Morrone; Vincenzo Venerito; Luca Cantarini; Giacomo Emmi; Gerard Espinosa; Gema M. Lledó; Marta Mosca; Rosaria Talarico; Alberto Cauli; Matteo Piga; Jurgen Sota; Claudia Fabiani; Emanuele Chiara; Edoardo Biancalana; Irene Mattioli; Lorenza Maria Argolini; Federica Di Cianni; Roberto Caporali; Florenzo Iannone

doi:10.1093/rheumatology/keae274

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Oral and genital ulcers are the hallmark manifestation of Behçet's disease (BD), significantly impacting patients' quality of life. Our study focuses on comparing the effectiveness and safety of TNF inhibitors (TNFis) and apremilast in controlling oral ulcers of BD, aiming to provide evidence-based guidance for physicians in selecting appropriate treatment modalities.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lopalco et al. (2024) studied this question.

synapsesocial.com/papers/68e67e05b6db6435876073ed https://doi.org/10.1093/rheumatology/keae274

View at Publisher

Ask AI

Bookmark

Share

Exploring relief for Behçet’s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast

Ask about this paper

Abstract

Discussion

Cite This Study

Exploring relief for Behçet’s disease refractory oral ulcers: a comparison of TNF inhibitors versus apremilast

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading